Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact

This article was originally published in The Pink Sheet Daily

Executive Summary

The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.

You may also be interested in...



Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition

While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.

Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon

FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.

Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon

FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.

Related Content

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel